Article
Regulatory Compliance

Mandatory GRAS notification is coming to the US

On August 11, 2026, FDA published a proposed rule that would make GRAS notifications mandatory and significantly increase agency visibility into ingredients marketed under independent GRAS conclusions. If finalized, companies relying on self-affirmed GRAS determinations for certain uses in human or animal food would generally be required to notify FDA, unless an exception applies. This proposed shift could have a significant impact on companies currently marketing products based on self-affirmed GRAS conclusions.

FDA Regulatory Update

Docket FDA-2025-N-3262 21 CFR Parts 170 & 570 91 FR 51834
days left in the public comment period — closes December 9, 2026

01 — Context

What’s Actually Changing

Until now, a company could decide on its own — internally, without ever telling the FDA — that an ingredient was “Generally Recognized As Safe.” This self-affirmation remains, today, entirely legal. The proposed rule seeks to end the ability to rely on such GRAS conclusions without notifying FDA.

Today — voluntary system

  • A company can self-affirm an ingredient’s GRAS status without ever notifying the FDA.
  • Filing a GRAS Notice remains optional — many self-affirmed ingredients are never reviewed by the FDA at all.
  • No reliable public list tracks the real status of every ingredient on the market.
Aug 11, 2026 Proposed rule published in the Federal Register
Dec 9, 2026 Public comment period closes
Final rule +60d Effective date (estimated)
+12 months Streamlined pathway closes
+18 months Full compliance deadline
The critical point: eligibility for the streamlined transitional pathway will depend on whether the substance was already introduced into U.S. interstate commerce before the effective date of the final rule, not on when you prepare your file. Companies should start documenting their commercial history now to avoid missing out on this lighter pathway.
What exemptions are proposed?
  • The FDA has already issued a “No Questions” letter covering the substance and its intended use.
  • The substance is already listed or affirmed as GRAS in FDA regulations (21 CFR Parts 182, 184 or 186).
  • The substance qualifies as GRAS under certain provisions of 21 CFR § 170.30.
  • The intended use has already been reviewed through an established FDA process, with no GRAS Notice required.
  • A Threshold of Regulation (TOR) exemption or a Food Contact Notification (FCN) already applies.
  • The substance qualifies for the proposed streamlined pathway for certain substances already in interstate commerce.

02 — Diagnostic

Where Do You Actually Stand?

Pick the profile that matches your business, then flag every situation that applies to you. You’ll get an exposure read and a recommended next step.

03 — Your options

How FoodChain ID Can Help

Affected companies generally take two paths, often combined: first, verify what they know about their ingredients and their regulatory status; then, take the appropriate steps to document or support their GRAS status and, where required, notify FDA.

Recommended for you

Regulatory Solution

Supplements R&D Insight

Check your ingredients’ real US regulatory status in minutes: already listed as authorized food additive or GRAS in the Code of Federal Regulations (CFR), notified (GRAS notices, NDI notifications), public self-affirmed GRAS, or absent from any known filing.

3.1k

Regulatory statuses tracked and updated daily across North America, Europe, and ASEAN.

315k

Finished-product references to benchmark your own formulations.

A–Z

Ingredient-by-ingredient status mapping, claims, and studies in one search.

Explore Supplements R&D Insight →
Recommended for you

Expert support

Regulatory Consulting

Our experts work with you to build your compliance strategy, from status assessment through to a filed notification.

01

Status assessment already authorized according to the US law, already notified or tailored GRAS strategy.

02

Preparation and filing of the FDA notification (GRAS Notice).

03

Response to FDA questions during the review period.

Learn more about our GRAS service →

Most companies combine both: Supplements R&D Insight to diagnose, Consulting to act.

Questions about your regulatory exposure?

Our team can review your ingredient portfolio and tell you what to do next before the comment period closes.

"(Required)" indicates required fields

Signals flagged
0/5
array(4) { ["gated"]=> string(2) "no" ["gated_type"]=> string(6) "string" ["cookie"]=> string(6) "ABSENT" ["cookie_type"]=> NULL }

Stay up to date with our newsletter

This field is for validation purposes and should be left unchanged.